Sleep Cycle (SLEEP) Hisse Özeti
Sleep Cycle AB (publ), İsveç'te uyku takibi uygulamaları sağlamakla ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 3/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 3/6 |
SLEEP Community Fair Values
Create NarrativeSee what 67 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
ZenaTech: A big bet on the rise of AI drones and drones-as-a-service
Key Takeaways ZenaTech is focusing its efforts into building AI drones, combining Drone as a Service, SaaS, and AI as its key revenue drivers. Previously building software for agriculture, ZenaTech has shifted rapidly toward drone services, now driving ~70% of revenue after recent acquisitions.
Read full narrativeSleep Cycle AB (publ) Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | SEK 15.34 |
| 52 Haftanın En Yüksek Seviyesi | SEK 34.70 |
| 52 Haftanın En Düşük Seviyesi | SEK 14.84 |
| Beta | 0.013 |
| 1 Aylık Değişim | -12.34% |
| 3 Aylık Değişim | -36.08% |
| 1 Yıllık Değişim | -50.52% |
| 3 Yıllık Değişim | -65.06% |
| 5 Yıllık Değişim | n/a |
| Halka arzdan bu yana değişim | -80.78% |
Son Haberler & Güncellemeler
Recent updates
Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00
May 02
SLEEP: Respiratory Research And Apnea Launch Will Support 2027 Margin Recovery
Analysts keep their SEK35.0 price target for Sleep Cycle unchanged, citing offsetting shifts in key model inputs such as slightly lower revenue growth assumptions, a reduced profit margin outlook, a marginally lower discount rate and a higher future P/E multiple. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping its premium features bundled into Revolut’s Premium, Metal and Ultra tiers and extending reach to Revolut’s global user base (Client Announcements).
SLEEP: Respiratory Disease Research Collaboration Will Drive Long Term Upside Potential
Analysts now see Sleep Cycle's fair value at SEK 30.75, down from SEK 39.50, reflecting updated views on revenue growth, profit margins and an outlook that applies a higher discount rate along with a much higher future P/E assumption. What's in the News Sleep Cycle introduced an AI-powered Sleep Score that focuses on duration, quality and routine.SLEEP: Respiratory Research Collaborations Will Support 2027 Margin Recovery Upside
Analysts have maintained their SEK 35.00 price target on Sleep Cycle, with only small tweaks to assumptions around discount rate, revenue, profit margin and future P/E, reflecting a broadly steady outlook on the shares. What's in the News Sleep Cycle began a five-year research collaboration with The Delphi Group at Carnegie Mellon University, providing deidentified sleep-based cough and breathing data to support research on respiratory disease surveillance and early detection of seasonal and emerging outbreaks, including influenza, RSV and SARS-CoV-2.SLEEP: Research Partnerships And 2027 Margin Recovery Will Drive Long Term Upside
Analysts are keeping their SEK price target for Sleep Cycle unchanged. A fair value of SEK 35.00 is maintained, as small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions effectively offset one another.SLEEP: Licensing Deals And 2027 Margin Recovery Will Drive Long Term Upside
Analysts have reduced their Sleep Cycle fair value estimate from SEK 43.0 to SEK 35.0, reflecting a higher discount rate, a lower assumed future P/E, and slightly softer margin expectations, partly offset by a higher projected revenue growth rate. What's in the News Sleep Cycle issued earnings guidance indicating an EBIT margin of about 5% for 2026, linked to increased forward-looking investments.These Analysts Just Made An Downgrade To Their Sleep Cycle AB (publ) (STO:SLEEP) EPS Forecasts
Feb 09Sleep Cycle (STO:SLEEP) Has Announced That Its Dividend Will Be Reduced To SEK0.53
Feb 07
SLEEP: Data Partnerships Will Drive Future Upside For This Undervalued Play
Analysts have lifted their price target for Sleep Cycle from $26.00 to $34.50, citing updated assumptions that combine a lower discount rate and higher projected profit margin with a different revenue growth outlook and a higher future P/E multiple. What's in the News Sleep Cycle and the UK Health Security Agency began a 12 week research collaboration to test whether anonymised, privacy preserved data from the Sleep Cycle app and its Cough Radar tool can support respiratory disease surveillance and early detection of patterns for viruses such as influenza, RSV and Covid 19 (Key Developments).SLEEP: Expanding Licensing And AI Coaching Will Drive Long Term Upside
Analysts have maintained their fair value estimate for Sleep Cycle at $43.00. They cite more cautious assumptions on revenue growth and profit margins, together with a higher future P/E outlook, as key factors behind the unchanged target.SLEEP: Expanding Licensing And AI Sleep Coaching Will Support Long Term Upside
Analysts have kept their fair value estimate for Sleep Cycle steady at US$43.00, pointing to only small tweaks in the discount rate, expected revenue growth and profit margin, along with a slightly lower future P/E assumption as the basis for the unchanged target. What's in the News Sleep Cycle signed a multi year SDK licensing agreement with a global IoT and smart home device brand, allowing the customer to integrate the company’s audio based sleep tracking analysis into its devices and broadening Sleep Cycle’s technology licensing activity (Key Developments).There's No Escaping Sleep Cycle AB (publ)'s (STO:SLEEP) Muted Earnings
Jan 04SLEEP: Long Term Profit Margins Will Drive Stronger Future Upside Potential
Analysts have trimmed their price target on Sleep Cycle from approximately $49.00 to $43.00. This reflects expectations for slower revenue growth, partially offset by higher long term profit margins and a lower future price to earnings multiple.Sleep Cycle AB (publ) (STO:SLEEP) Held Back By Insufficient Growth Even After Shares Climb 30%
Sep 09Weekly Picks: 💸 A dividend-rich sleep-tech play few investors are watching, and 2 other picks.
Aug 27
Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model
Q2 2025 Update (updated 250823) Subscriptions continue to decline (-3%), leading to a top-line contraction that is likely to persist. However, partnerships are gaining momentum , with the company highlighting on the conference call that these could carry a more favorable margin profile.Expanding Technology And Sleep Apnea Initiatives Will Open New Opportunities
Sleep Cycle’s consensus price target has been revised upward, driven primarily by an increase in its future P/E multiple and a modest improvement in net profit margin, resulting in a new fair value estimate of SEK44.75. What's in the News Launched in-app promotion platform in collaboration with HelloFresh, Factor, and YouFoodz, enabling external brands to target Sleep Cycle’s user base with curated wellness offers and supporting expansion of partnership programs.Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts
Apr 30The Market Doesn't Like What It Sees From Sleep Cycle AB (publ)'s (STO:SLEEP) Earnings Yet As Shares Tumble 34%
Apr 29Sleep Cycle's (STO:SLEEP) Dividend Will Be Increased To SEK3.00
Apr 08
Medical-Grade Sleep Apnea Certification Will Open New Healthcare Partnerships
Exploring medical-grade certification and new revenue streams could enhance profitability, opening healthcare markets through partnerships and innovation.Sleep Cycle's (STO:SLEEP) Upcoming Dividend Will Be Larger Than Last Year's
Mar 06Sleep Cycle (STO:SLEEP) Is Paying Out A Larger Dividend Than Last Year
Feb 10Sleep Cycle's Revenue Set to Rise 10% with Strong Business Model
Company will continue its trajectory of 10% top line growth p.a. with possibility of more aggressive growth should new business materialize (e.g. data monetization or making the app medical device forHissedar Getirileri
| SLEEP | SE Software | SE Pazar | |
|---|---|---|---|
| 7D | -17.9% | 0.7% | -1.9% |
| 1Y | -50.5% | -41.7% | 11.0% |
Getiri vs. Endüstri: SLEEP geçen yıl % -41.7 oranında getiri sağlayan Swedish Software sektörünün gerisinde kaldı.
Getiri vs Piyasa: SLEEP geçen yıl % 11 oranında getiri sağlayan Swedish Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| SLEEP volatility | |
|---|---|
| SLEEP Average Weekly Movement | 7.7% |
| Software Industry Average Movement | 9.3% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.8% |
İstikrarlı Hisse Senedi Fiyatı: SLEEP son 3 ayda Swedish piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: SLEEP 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2001 | 39 | Erik Jivmark | sleepcycle.com |
Sleep Cycle AB (publ), İsveç'te uyku izleme uygulamaları sağlamakla ilgilenmektedir. Uyku ve sağlık platformları geliştirmektedir. Şirket, uyku ile ilgili çözümler sağlayan bir uygulama olan Sleep Cycle uygulamasını sunmaktadır.
Sleep Cycle AB (publ) Temel Bilgiler Özeti
| SLEEP temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | SEK 311.06m |
| Kazançlar(TTM) | SEK 44.92m |
| Gelir(TTM) | SEK 235.96m |
SLEEP aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| SLEEP gelir tablosu (TTM) | |
|---|---|
| Gelir | SEK 235.96m |
| Gelir Maliyeti | SEK 100.65m |
| Brüt Kâr | SEK 135.31m |
| Diğer Giderler | SEK 90.39m |
| Kazançlar | SEK 44.92m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 26, 2026
| Hisse başına kazanç (EPS) | 2.22 |
| Brüt Marj | 57.34% |
| Net Kâr Marjı | 19.04% |
| Borç/Özkaynak Oranı | 0% |
SLEEP uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/04 22:53 |
| Gün Sonu Hisse Fiyatı | 2026/05/04 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Sleep Cycle AB (publ) 4 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Oscar Erixon | Carnegie Investment Bank AB |
| Erik Granström | DNB Carnegie |
| Rikard Engberg | DNB Carnegie Commissioned Research |